Similar articles

• [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].

  Bazinski H, Jensen HB, Stenager E. Bazinski H, et al. Ugeskr Laeger. 2015 May 11;177(20):956-60. Ugeskr Laeger. 2015. PMID: 26535431 Review. Danish.
• [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].

  Basinski H, Jensen HB, Stenager E. Basinski H, et al. Ugeskr Laeger. 2014 Mar 17;176(12A):V09130552. Ugeskr Laeger. 2014. PMID: 25350886 Review. Danish.
• The therapeutic use of cannabinoids: Forensic aspects.

  Indorato F, Liberto A, Ledda C, Romano G, Barbera N. Indorato F, et al. Forensic Sci Int. 2016 Aug;265:200-3. doi: 10.1016/j.forsciint.2016.03.031. Epub 2016 Mar 23. Forensic Sci Int. 2016. PMID: 27038587
• The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.

  Marinelli L, Mori L, Canneva S, Colombano F, Currà A, Fattapposta F, Bandini F, Capello E, Abbruzzese G, Trompetto C. Marinelli L, et al. Int Clin Psychopharmacol. 2016 Jul;31(4):232-9. doi: 10.1097/YIC.0000000000000126. Int Clin Psychopharmacol. 2016. PMID: 27003093
• Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis.

  Sorosina M, Clarelli F, Ferrè L, Osiceanu AM, Unal NT, Mascia E, Martinelli V, Comi G, Benigni F, Esposito F, Martinelli Boneschi F. Sorosina M, et al. Eur J Neurol. 2018 Jul;25(7):934-e70. doi: 10.1111/ene.13623. Epub 2018 Apr 16. Eur J Neurol. 2018. PMID: 29528549